These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 15024400

  • 1. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
    Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA.
    Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
    [Abstract] [Full Text] [Related]

  • 2. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [Abstract] [Full Text] [Related]

  • 3. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [Abstract] [Full Text] [Related]

  • 4. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [Abstract] [Full Text] [Related]

  • 5. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [Abstract] [Full Text] [Related]

  • 6. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.
    Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
    [Abstract] [Full Text] [Related]

  • 7. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [Abstract] [Full Text] [Related]

  • 8. The effect of pioglitazone on the liver: role of adiponectin.
    Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.
    Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
    [Abstract] [Full Text] [Related]

  • 9. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
    Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA.
    Gastroenterology; 2007 Aug; 133(2):496-506. PubMed ID: 17681171
    [Abstract] [Full Text] [Related]

  • 10. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L, Kotronen A, Granér M, Yki-Järvinen H.
    J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
    [Abstract] [Full Text] [Related]

  • 11. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 12. Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: possible role of the resistin and adiponectin.
    Yang G, Li L, Tang Y, Boden G.
    Biochem Biophys Res Commun; 2006 Jan 27; 339(4):1190-6. PubMed ID: 16338222
    [Abstract] [Full Text] [Related]

  • 13. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes.
    Juurinen L, Tiikkainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H.
    Am J Physiol Endocrinol Metab; 2007 Mar 27; 292(3):E829-35. PubMed ID: 17090752
    [Abstract] [Full Text] [Related]

  • 14. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.
    Diabetes Care; 2001 Apr 27; 24(4):710-9. PubMed ID: 11315836
    [Abstract] [Full Text] [Related]

  • 15. Effects of free fatty acids on plasma resistin and insulin resistance in awake rats.
    Yang G, Li L, Fang C, Zhang L, Li Q, Tang Y, Boden G.
    Metabolism; 2005 Sep 27; 54(9):1142-6. PubMed ID: 16125524
    [Abstract] [Full Text] [Related]

  • 16. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec 27; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 17. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.
    Cusi K, DeFronzo R.
    J Clin Endocrinol Metab; 2000 Sep 27; 85(9):3077-84. PubMed ID: 10999789
    [Abstract] [Full Text] [Related]

  • 18. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.
    Diabetes Care; 2006 Nov 27; 29(11):2371-7. PubMed ID: 17065670
    [Abstract] [Full Text] [Related]

  • 19. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes.
    Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H.
    Gastroenterology; 2008 Jul 27; 135(1):122-30. PubMed ID: 18474251
    [Abstract] [Full Text] [Related]

  • 20. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabetes; 2008 Sep 27; 57(9):2288-95. PubMed ID: 18535187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.